ELOX

Eloxx Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-17

Figures on this page computed 2026-11-08 12:40 UTC

Last close

12.74USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-17

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-11
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-11
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
- 10-K for 2025, filed 2026-03-17
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
- 10-K for 2025, filed 2026-03-17
- 10-Q for 2025, filed 2026-08-11
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.02 against 0.52 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
Price: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.00x

0.20x

n/a

0.14x

1.53x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-17

Sales0.00x
Its own average over 3 years, 2.1M.
Profit0.20x
Its own average over 10 years, -29.3M.
Free cash flown/a
Its own average over 6 years, -27.2M.
Debt0.14x
Its own average over 9 years, 7.3M.
Price1.53x
Its own average over 6 years, 8. Market data, 2026-11-04

Sales is furthest from its own average, at 0.00 times.

Sales is 0.00 times its own 3-year average; Profit is 0.20 times its own 10-year average; Debt is 0.14 times its own 9-year average; Price is 1.53 times its own 6-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-17

Sales against its own 3-year average0.00
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
The filing itself
Profit against its own 10-year average0.20
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
The filing itself
Free cash flow against its own 6-year averagen/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
The filing itself
Debt against its own 9-year average0.14
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-108687
Reported in
USD
The filing itself
Price against its own 6-year average1.53Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD